Unexpected delays, infighting and a staffing crisis are fueling investors’ unease.
Source link
About The Author
Heard on the Street: The Trump administration’s ambition to unleash biomedical innovation and sharpen America’s edge against China is colliding with a far messier reality inside the FDA